EP Patent

EP4616904A3 — A formulation comprising selexipag

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2025-10-29 · 1y expired

What this patent protects

The present invention relates to a tablet formulation comprising selexipag form III, wherein selexipag form III has a d (0.9) particle size between 1 µm to 150 µm. Furthermore, the tablet is obtained using an effective process.

USPTO Abstract

The present invention relates to a tablet formulation comprising selexipag form III, wherein selexipag form III has a d (0.9) particle size between 1 µm to 150 µm. Furthermore, the tablet is obtained using an effective process.

Drugs covered by this patent

Patent Metadata

Patent number
EP4616904A3
Jurisdiction
EP
Classification
—
Expires
2025-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.